Weekly Analysts’ Ratings Updates for Omeros (OMER)

Several analysts have recently updated their ratings and price targets for Omeros (NASDAQ: OMER):

• 1/10/2026 – Omeros was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/8/2026 – Omeros had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
• 1/8/2026 – Omeros had its price target raised by analysts at HC Wainwright from $20.00 to $40.00. They now have a “buy” rating on the stock.
• 12/24/2025 – Omeros had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 12/24/2025 – Omeros had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
• 12/13/2025 – Omeros was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/1/2025 – Omeros had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
• 11/15/2025 – Omeros was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/14/2025 – Omeros had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.